Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A narrative review of the literature: The role of biologics and JAK inhibitors in vitiligo.
Australas J Dermatol
November 2024
Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Article Synopsis
- * While treatments for other skin disorders have advanced, progress in vitiligo treatment has been limited, with few studies on biologics.
- * Recent findings suggest that JAK inhibitors may be effective, and this paper reviews existing case reports and studies on systemic therapies for vitiligo.
Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022.
Arthritis Rheumatol
December 2024
University of California, San Francisco and Zuckerberg San Francisco General Hospital.
Objective: Biosimilars have the potential to reduce spending on biologic drugs, yet uptake has been slower than anticipated. We investigated how successive introductions of infliximab biosimilars influenced their adoption by major US insurance providers.
Methods: Data came from the Rheumatology Informatics System for Effectiveness, a national registry with electronic health records from more than 1,100 US rheumatologists.
Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective.
J Manag Care Spec Pharm
November 2024
Sandoz Inc., Princeton, NJ.
Article Synopsis
- The biosimilar market is expanding quickly, with numerous approvals and product launches expected to increase competition for adalimumab, potentially lowering costs for payers across various medical fields.
- A budget impact model was created to analyze the financial implications of introducing biosimilar adalimumab to a US commercial health plan, factoring in various conversion rates and price reductions.
- The model showed significant cost savings, with potential reductions of over $28 million when switching from reference adalimumab to biosimilars, even with modest conversion rates and slight price cuts; additional office visit costs had minimal impact overall.
Dapagliflozin mitigates oxidative stress, inflammatory, and histopathological markers of aging in mice.
J Med Life
February 2024
Department of Pharmacology, College of Health and Medical Technology, Uruk University, Baghdad, Iraq.
Aging, a complex physiological process affecting all living things, is a major area of research, particularly focused on interventions to slow its progression. This study assessed the antiaging efficacy of dapagliflozin (DAPA) on various aging-related parameters in a mouse model artificially induced to age. Forty male Swiss albino mice were randomly divided into four groups of ten animals each.
View Article and Find Full Text PDFEarly identification of golimumab-treated patients with higher likelihood of long-term retention.
Front Immunol
April 2024
Departamento de Reumatología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
Background: The early identification of patients' profiles most likely to respond to and maintain long-term therapy with a biological drug can have clinical and cost-effectiveness implications.
Objectives: To evaluate the utility of an innovative approach for early identification of patient profiles associated with long-term persistence of golimumab, a tumour necrosis factor inhibitor, in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (SpA) under real-world conditions.
Design: Retrospective non-interventional database analysis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!